Valuation: AstraZeneca PLC

Market Cap 251B 226B 210B 191B 358B 23,874B 360B 2,526B 986B 12,391B 942B 921B 39,852B P/E 2026 *
21.1x
P/E 2027 * 18.2x
Enterprise Value 271B 243B 227B 206B 387B 25,772B 389B 2,727B 1,065B 13,376B 1,017B 995B 43,019B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.91x
Free-Float
96.62%
Yield 2026 *
2.07%
Yield 2027 * 2.19%
1 day+3.72%
Current month+81.90%
Current year+83.56%
Current year 89.04
Extreme 89.04
169.81
1 year 80.48
Extreme 80.48
169.81
3 years 60.47
Extreme 60.47
169.81
5 years 52.65
Extreme 52.65
169.81
10 years 25.55
Extreme 25.55
169.81
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+3.71%+1.19% - - 251B
+4.36%+7.85%+52.61%+104.56% 1,077B
+2.29%+1.48%+36.15%+65.23% 612B
+2.26%+6.26%+27.96%+96.61% 501B
+1.73%+5.78%+79.06%+44.62% 364B
+1.71%+7.29%+33.19%+50.07% 353B
+1.88%+6.69%+20.72%+44.04% 278B
+3.00%+7.00%+0.63%+15.97% 251B
+2.83%+7.99%+47.99%+53.37% 230B
+2.81%+7.87%+34.13%+100.35% 190B
Average +2.71%+2.33%+36.94%+63.87% 428.5B
Weighted average by Cap. +2.92%+1.75%+40.64%+73.26%

Financials

2026 *2027 *
Net sales 63.37B 56.98B 53.17B 48.19B 90.48B 6,031B 91.04B 638B 249B 3,130B 238B 233B 10,067B 67.24B 60.45B 56.41B 51.13B 95.99B 6,398B 96.59B 677B 264B 3,321B 252B 247B 10,681B
Net income 11.81B 10.61B 9.91B 8.98B 16.85B 1,123B 16.96B 119B 46.42B 583B 44.32B 43.36B 1,875B 13.73B 12.34B 11.52B 10.44B 19.6B 1,307B 19.72B 138B 53.98B 678B 51.54B 50.43B 2,181B
Net Debt 19.94B 17.93B 16.73B 15.16B 28.47B 1,898B 28.65B 201B 78.4B 985B 74.87B 73.24B 3,168B 12.31B 11.06B 10.32B 9.36B 17.57B 1,171B 17.68B 124B 48.38B 608B 46.2B 45.2B 1,955B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-15 US$168.63 +4.07% 1,199,515
26-10-14 US$162.03 +3.99% 3,333,925
26-10-13 US$155.82 -1.59% 3,112,422
26-10-12 US$158.33 -0.55% 2,855,694
26-10-09 US$159.20 +0.26% 2,121,775
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
161.75USD
Average target price
209.01USD
Spread / Average Target
+29.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC